

Approved



**Burundi**

**Country Operational Plan**

**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		12,502,340	1,898,862	14,401,202	1,601,138	16,002,340
DOD		1,267,660		1,267,660	90,000	1,357,660
<b>Total</b>	<b>0</b>	<b>13,770,000</b>	<b>1,898,862</b>	<b>15,668,862</b>	<b>1,691,138</b>	<b>17,360,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency		On Hold Amount	Total
	DOD	USAID		
HBHC	6,252	660,412	0	666,664
HKID		799,517	0	799,517
HLAB	150,000	200,000	0	350,000
HTXD		0	0	0
HTXS	123,206	4,292,785	0	4,415,991
HVCT	193,840	2,718,394	0	2,912,234
HVMS	0	0	0	0
HVOP	451,440	736,875	0	1,188,315
HVSI	300,000	835,000	0	1,135,000
HVTB	6,786	184,478	0	191,264
MTCT	23,757	1,541,861	0	1,565,618
OHSS		1,743,684	0	1,743,684
PDCS	6,664	187,092	0	193,756
PDTX	5,715	501,104	0	506,819
	<b>1,267,660</b>	<b>14,401,202</b>	<b>0</b>	<b>15,668,862</b>

Approved





## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	666,664	0
HKID	799,517	0
HVTB	191,264	0
PDCS	193,756	0
<b>Total Technical Area Planned Funding:</b>	<b>1,851,201</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	350,000	0
HVSI	1,135,000	0
OHSS	1,743,684	0
<b>Total Technical Area Planned Funding:</b>	<b>3,228,684</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	2,912,234	0
HVOP	1,188,315	0
MTCT	1,565,618	0
<b>Total Technical Area Planned Funding:</b>	<b>5,666,167</b>	<b>0</b>

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
-------------	----------------------------	----------------

Approved



HTXS	4,415,991	0
PDTX	506,819	0
<b>Total Technical Area Planned Funding:</b>	<b>4,922,810</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	160,666
	Number of new ANC and L&D clients	171,956
	By: Known positives at entry	572
	By: Number of new positives identified	978
	Sum of Positives Status disaggregates	1,550
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	160,666
	New on ART	1,103
	Already on ART at beginning of current pregnancy	783
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	
	New on ART	0
	Already on ART at beginning of current pregnancy	0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting	n/a



	period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,572
	Total number of people in the target population	53,700
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	



	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	19,187
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	3,385
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,203
	Total estimated number of key population in the catchment area	29,482
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,544
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level	



	HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,659
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females	



	who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	5,352
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female	24,130



	sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	449,826
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	



	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	



	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,740
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	102,595
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,750
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	331,741
	Test Result by Aggregated Age and Sex: Negative <15 Male	7
	Test Result by Aggregated Age and Sex: Negative 15+ Male	123
	Test Result by Aggregated Age and Sex: Negative <15 Female	9
	Test Result by Aggregated Age and Sex: Negative 15+ Female	448



Test Result by Aggregated Age and Sex: Positive <15 Male	61
Test Result by Aggregated Age and Sex: Positive 15+ Male	2,405
Test Result by Aggregated Age and Sex: Positive <15 Female	141
Test Result by Aggregated Age and Sex: Positive 15+ Female	6,440
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	
Service Delivery Point (Community): Mobile testing	12,988
Service Delivery Point (Community): Other	
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	
Service Delivery Point (Community) by Age: 15+ homebased testing	
Service Delivery Point (Community) by Age: <15 mobile testing	
Service Delivery Point (Community) by Age: 15+ mobile testing	
Service Delivery Point (Community) by Age: <15 other	



	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	246
	Service Delivery Point (Facility): Outpatient	60,245
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	178,384
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	158,655
	Service Delivery Point (Facility): TB Clinics	5,300
	Service Delivery Point (Facility): Index testing	34,007
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	



	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and	2,926



	relapsed TB cases with documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	2,976
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	422
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered	1,168



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	323
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,013
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	92
	Total number of registered new and relapsed TB cases, during the reporting period.	115
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total	



	number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	449
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	4
	Age/Sex: 10-14 Female	10
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	15
	Age/Sex: 25-49 Female	10
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	14
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	42
By type of service: Sexual Violence (Post-Rape Care)	407	
By PEP service provision (related to sexual violence services provided)	407	



	Age/Sex: 15-19 Female	24
	Age/Sex: 15-19 male	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,500
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
Required only for DREAMS countries - By service, age and		



	sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and	



	sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening	



	Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	5,500
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	



TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male &lt;15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Female &lt;15</p>	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	665
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	665
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB	



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	75



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	241
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	263
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	40,043
	Screened for TB by Age/Sex:<15 Male	1,603
	Screened for TB by Age/Sex: 15+ Male	11,837
	Screened for TB by Age/Sex:<15 Female	1,914



	Screened for TB by Age/Sex: 15+ Female	24,689
	Screen Result: Screened Positive for TB	8,011
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	8,011
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	4,647
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1,524
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,213
	Screened for TB by Age/Sex: <15 Male	19
	Screened for TB by Age/Sex: 15+ Male	716
	Screened for TB by Age/Sex: <15 Female	29
	Screened for TB by Age/Sex: 15+ Female	449
	Screen Results: Screened Positive for TB	249



	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	218
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	759
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	253
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	597
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,289
	Sum of Infant Age disaggregates	1,886



	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	8
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	32
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	41,111
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	1,586	



	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	12,420
	Aggregated Age/Sex: <15 Female	2,708
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	24,397
	Sum of Aggregated Age/Sex <15	4,294
	Sum of Aggregated Age/Sex 15+	36,817
	Sum of Aggregated Age/Sex disaggregates	41,111
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,553
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	1,310
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	2,737
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1,436
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	4,934
	Sum of Aggregated Age/Sex disaggregates	10,417
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART	n/a



	patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	36,609
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	40,853
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	



	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	



	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	30,957
	Numerator: Indication: Targeted	5,652
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	34,522
	Denominator: Indication: Targeted	6,331
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	



	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	



	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	1,090
	Numerator Aggregated Age/Sex: 15+ Male	10,819
	Numerator Aggregated Age/Sex: <15 Female	1,358



	Numerator Aggregated Age/Sex: 15+ Female	22,772
	Denominator Aggregated Age/Sex: <15 Male	1,283
	Denominator Aggregated Age/Sex: 15+ Male	12,018
	Denominator Aggregated Age/Sex: <15 Female	1,596
	Denominator Aggregated Age/Sex: 15+ Female	25,141
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,057
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,363
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at	



	12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the</p>	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,154
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	135



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,566
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,289
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	155
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	2,849



	including those who have died, those who have stopped ART, and those lost to follow-up)	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	213
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	CD4: Number of laboratories that perform this testing	19
	CD4: Number of laboratories that participate in this PT program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	2
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing	



	criteria in this PT program	
	HIV viral load: Number of laboratories that perform this testing	3
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST):	



	Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	300
	By Graduates: Doctors	
	By Graduates: Nurses	300
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	300



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
16663	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,597,647
16664	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	4,747,160
16770	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	600,000
17119	FHI 360	NGO	U.S. Department of Defense	GHP-State	300,739
17520	Engender Health	Private Contractor	U.S. Agency for International Development	GHP-State	750,000
17521	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-USAID	800,000
17522	Population Services International	NGO	U.S. Department of Defense	GHP-State	666,921
17552	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,200,000
17553	Metabiota	Private Contractor	U.S. Department of Defense	GHP-State	150,000



17556	U.S. Department of Defense Naval Health Research Center	Own Agency	U.S. Department of Defense	GHP-State	150,000
18407	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	2,353,388
18408	FHI 360	NGO	U.S. Agency for International Development	GHP-State	799,517
18409	TBD	TBD	Redacted	Redacted	Redacted
18419	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 16663</b>	<b>Mechanism Name: Integrated Health Project</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,597,647</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,597,647</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,597,647

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16663</b>			
<b>Mechanism Name: Integrated Health Project</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	34,474	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	52,092	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	82,724	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	130,194	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	688,329	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	619,897	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	857,128	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	132,809	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,334
PMTCT_ART_DSD	New on ART	432
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	234
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	68,334
PMTCT_STAT_DSD	Number of new ANC and L&D clients	71,930



PMTCT_STAT_DSD	By: Known positives at entry	107
PMTCT_STAT_DSD	By: Number of new positives identified	440
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	547
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	155,008
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,701
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,849
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,106
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	118,352
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,807
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	151,201
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	155,008
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	16
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	836
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	17
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,944
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	17,155
HTC_TST_DSD	Service Delivery Point (Facility): VCT	57,051
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	66,324
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,101
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	13,377
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	852
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	902



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	316
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	68
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	420
GEND_GBV_DSD	Number of people receiving post-GBV care	110
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	110
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	110
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	69
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	69
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The	11



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	9,195
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	645
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,694
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	667
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,189
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,838
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,838
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	386
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	280
PMTCT_EID_DSD	Sum of Infant Age disaggregates	666
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	10
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,195
TX_CURR_TA	Aggregated Age/Sex: <15 Male	618
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,694
TX_CURR_TA	Aggregated Age/Sex: <15 Female	667



TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,216
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,285
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,910
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,195
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,725
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	504
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	604
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	568
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,049
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,725
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,276
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,195
TX_PVLS_TA	Numerator: Indication: Routine	8,276
TX_PVLS_TA	Denominator: Indication: Routine	9,195
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	214
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,540
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	219
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	5,303
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	310
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	2,835
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	333
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	5,717
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	955
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,052



	stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	282
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	609
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	317
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	666
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	173



LAB_PT_DSD	CD4: Number of laboratories that perform this testing	6
------------	---	---

**Implementing Mechanism Details**

<b>Mechanism ID: 16664</b>	<b>Mechanism Name: PMTCT Acceleration Project</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,747,160</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,747,160</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,648,298
GHP-USAID	1,098,862

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16664</b>			
<b>Mechanism Name: PMTCT Acceleration Project</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	92,277	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	132,386	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	87,758	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,223,595	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	695,551	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,231,298	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	284,295	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	89,932
PMTCT_ART_DSD	New on ART	671
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	510
PMTCT_ART_TA	New on ART	0
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	89,932
PMTCT_STAT_DSD	Number of new ANC and L&D clients	94,665
PMTCT_STAT_DSD	By: Known positives at entry	465
PMTCT_STAT_DSD	By: Number of new positives identified	497
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	962



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	265,720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,935
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	55,976
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,623
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	203,186
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,558
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	259,162
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	265,720
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Male	7
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Male	123
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Female	9
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Female	448
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	44
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,268
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	44
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,820
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	42,588
HTC_TST_DSD	Service Delivery Point (Facility): VCT	108,531
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	89,931
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,040



HTC_TST_DSD	Service Delivery Point (Facility): Index testing	20,630
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,074
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,074
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	374
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	852
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	255
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	593
GEND_GBV_DSD	Number of people receiving post-GBV care	257
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	42
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	215
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	215
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	409
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	409
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	56
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	143

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	64
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	146
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	30,848
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	958
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	9,143
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,247
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	19,500
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	6,173
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6,173
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	4,647
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1,524
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	172
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,009
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,181
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0



PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	22
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	30,848
TX_CURR_TA	Aggregated Age/Sex: <15 Male	958
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	9,143
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,034
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	18,713
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,992
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	27,856
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	30,848
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,503
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	806
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,017
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	868
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,812
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	7,503
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	27,763
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	30,843
TX_PVLS_TA	Numerator: Indication: Routine	22,211
TX_PVLS_TA	Numerator: Indication: Targeted	5,552
TX_PVLS_TA	Denominator: Indication: Routine	24,655
TX_PVLS_TA	Denominator: Indication: Targeted	6,188
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	876
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	8,279
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,139
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	17,469



TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	973
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	9,183
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,263
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	19,424
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,813
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,122
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	770
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,915
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	848



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,128
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	40
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	13
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	3
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	300
HRH_PRE	By Graduates: Nurses	300
HRH_PRE	Sum of Graduates disaggregated	300

### Implementing Mechanism Details

<b>Mechanism ID: 16770</b>	<b>Mechanism Name: USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	600,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16770		
<b>Mechanism Name:</b>	USAID Applying Science to Strengthen and Improve Systems (ASSIST)		
<b>Prime Partner Name:</b>	Project University Research Corporation, LLC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	516,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	84,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17119</b>	<b>Mechanism Name: FHI 360 Burundi</b>
Funding Agency: DOD	Procurement Type: Grant

Approved



Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,739</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,739</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,739

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	37,592
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	37,592
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building



**Budget Code Information**

<b>Mechanism ID:</b> 17119			
<b>Mechanism Name:</b> FHI 360 Burundi			
<b>Prime Partner Name:</b> FHI 360			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	5,314	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	5,813	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	6,664	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	58,463	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	90,288	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	23,757	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	104,725	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	5,715	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
-------------------------	--------------	-------------



PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,400
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	39
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,400
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,361
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	41
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	41
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,307
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,016
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	64
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,187
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	104
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,203
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,307
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	28
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	36



HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	246
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	502
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,400
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	159
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	92
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	115
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
GEND_GBV_DSD	Number of people receiving post-GBV care	2
GEND_GBV_DSD	Age/Sex: 20-24 Female	1
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	187
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	187
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The	12



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	82
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	82
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	935
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	15
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	552
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	22
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	346
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	192
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	168
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	721
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	240
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	39
PMTCT_EID_DSD	By infants who received their first virologic HIV test	0



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	39
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	815
TX_CURR_TA	Aggregated Age/Sex: <15 Male	9
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	386
TX_CURR_TA	Aggregated Age/Sex: <15 Female	6
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	414
TX_CURR_TA	Sum of Aggregated Age/Sex <15	15
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	800
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	815
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	136
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	68
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	68
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	136
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	570
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	815
TX_PVLS_TA	Numerator: Indication: Routine	470
TX_PVLS_TA	Numerator: Indication: Targeted	100
TX_PVLS_TA	Denominator: Indication: Routine	672
TX_PVLS_TA	Denominator: Indication: Targeted	143



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	110
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	136
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	73
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	39



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

**Implementing Mechanism Details**

<b>Mechanism ID: 17520</b>	<b>Mechanism Name: BRAVI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Engender Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 750,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 750,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	750,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17520</b>			
<b>Mechanism Name: BRAVI</b>			
<b>Prime Partner Name: Engender Health</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	106,875	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	45,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	80,625	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	436,875	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	80,625	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
GEND_GBVDSD	Number of people receiving post-GBV care	62
GEND_GBVDSD	Age/Sex: <10 Female	4
GEND_GBVDSD	Age/Sex: 10-14 Female	10
GEND_GBVDSD	Age/Sex: 20-24 Female	14
GEND_GBVDSD	Age/Sex: 25-49 Female	10
GEND_GBVDSD	Sum of Age/Sex Disaggregates	14
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	62
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	62
GEND_GBVDSD	Age/Sex: 15-19 Female	24

### Implementing Mechanism Details

<b>Mechanism ID: 17521</b>	<b>Mechanism Name: MEASURE Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	800,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 17521</b>			
<b>Mechanism Name: MEASURE Evaluation Phase IV</b>			
<b>Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	800,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17522</b>	<b>Mechanism Name: PSI Burundi</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 666,921</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 666,921</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	666,921

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	25,846
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	25,846
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID:</b> 17522
----------------------------



<b>Mechanism Name:</b> PSI Burundi			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	938	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	973	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	135,377	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	361,152	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	18,481	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,572
PP_PREV_DSD	Total number of people in the target population	53,700
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	19,187
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,385
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	16,077



	months	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	64
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,754
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,252
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	71
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,006
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	16,077
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	273
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	68
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	8,038
HTC_TST_DSD	Service Delivery Point (Facility): VCT	8,038
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	278
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	4
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	164
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	7
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	103
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	57
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	50
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear	38



	Only	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	13
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	253
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	197
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	54
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	251
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	253
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	53
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	48
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	5
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	53
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	43
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	53
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16

**Implementing Mechanism Details**

<b>Mechanism ID: 17552</b>	<b>Mechanism Name: Strengthening services for key populations/LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,200,000</b>	
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 1,200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,200,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17552		
<b>Mechanism Name:</b>	Strengthening services for key populations/LINKAGES		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	20,203



	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	29,482
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,544
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,659
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	5,352
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	24,130
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,764
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,764
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,764
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,764



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	572
HTC_TST_DSD	Service Delivery Point (Facility): VCT	4,764
GEND_GBV_DSD	Number of people receiving post-GBV care	18
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	18

**Implementing Mechanism Details**

<b>Mechanism ID: 17553</b>	<b>Mechanism Name: Metabiota Burundi</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Metabiota	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17553 <b>Mechanism Name:</b> Metabiota Burundi <b>Prime Partner Name:</b> Metabiota			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17556	<b>Mechanism Name:</b> DoD Mech Burundi (NHRC)
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense Naval Health Research Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 150,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 150,000	
Funding Source	Funding Amount
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	17556		
<b>Mechanism Name:</b>	DoD Mech Burundi (NHRC)		
<b>Prime Partner Name:</b>	U.S. Department of Defense Naval Health Research Center		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	136
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	136

### Implementing Mechanism Details

<b>Mechanism ID: 18407</b>	<b>Mechanism Name: PSM-GHSC</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,353,388</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,353,388</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,353,388



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18407			
<b>Mechanism Name:</b> PSM-GHSC			
<b>Prime Partner Name:</b> Global Health Supply Chain Program			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	126,786	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	16,610	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,050,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	425,845	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	226,413	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	307,734	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18408</b>	<b>Mechanism Name: Youth Power</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 799,517</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 799,517</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	799,517

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18408</b>			
<b>Mechanism Name: Youth Power</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	799,517	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,950
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,950
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,950
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,950
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	80
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	4,950
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,500
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,500

**Implementing Mechanism Details**

Mechanism ID: 18409	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 18419	TBD: Yes
REDACTED	

**Agency Information - Costs of Doing Business**

**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories



						and Applied Pipeline Amount
Computers/IT Services			0	83,600	0	83,600
ICASS			0	350,000	0	350,000
Institutional Contractors				335,000	0	335,000
Management Meetings/Professional Development			0	122,500	0	122,500
Non-ICASS Administrative Costs			0	31,500	0	31,500
Staff Program Travel		0	0	14,000	0	14,000
USG Staff Salaries and Benefits - Internationally Recruited		0	0	328,789	0	328,789
USG Staff Salaries and Benefits - Locally Recruited		0	0	335,749	0	335,749
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,601,138</b>	<b>0</b>	<b>1,601,138</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing

Approved



						<b>Business Categories and Applied Pipeline Amount</b>
ICASS		0		15,000	0	15,000
Institutional Contractors				0	0	0
Staff Program Travel				21,000	0	21,000
USG Staff Salaries and Benefits - Locally Recruited				54,000	0	54,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>90,000</b>	<b>0</b>	<b>90,000</b>